Nexus Pharmaceuticals drug gets FDA approval

LINCOLNSHIRE- Specialty and generic drugmaker Nexus Pharmaceuticals said the U.S. Food and Drug Administration has approved use of Busulfan Injection, the company's therapeutic equivalent for Busulfex.

Busulfan is used in combination with cyclophosphamide in the treatment of chronic myelogenous leukemia.

"The FDA approval of Busulfan continues to expand our portfolio of difficult to manufacture injectables, in addition to becoming our second oncology generic drug," said Nexus Chief Commercial Officer Omair Ahmed.

"Busulfan is currently on American Society of Health System Pharmacists drug shortage list," he added. "The addition of Busulfan will continue to show our commitment to providing patients and clinicians with access to affordable generic alternatives to critical need medicines that have a history of shortage."

Busulfan is expected to launch in the United States shortly in cartons of eight single-dose vials, the company said.